Antibiotic use and ileocolonic immune cells in patients receiving fecal microbiota transplantation for refractory intestinal GvHD: a prospective cohort study

Introduction: Treatment-refractory, acute graft-versus-host disease (GvHD) of the lower gastrointestinal tract (GI) after allogeneic hematopoietic stem cell transplantation is life threatening and lacks effective treatment options. While fecal microbiota transplantation (FMT) was shown to ameliorate GI-GvHD, its mechanisms of action and the factors influencing the treatment response in humans remain unclear. The objective of this study is to assess response to FMT treatment, factors influencing response, and to study the mucosal immune cell composition in treatment-refractory GI-GvHD. Methods: Consecutive patients with treatment-refractory GI-GvHD were treated with up to six endoscopically applied FMTs. Results: We observed the response to FMT in four out of nine patients with severe, treatment refractory GI-GvHD, associated with a significant survival benefit (p = 0.017). The concomitant use of broad-spectrum antibiotics was the main factor associated with FMT failure (p = 0.048). In addition, antibiotic administration hindered the establishment of donor microbiota after FMT. Unlike in non-responders, the microbiota characteristics (e.g. α- and β-diversity, abundance of anaerobe butyrate-producers) in responders were more significantly similar to those of FMT donors. During active refractory GI-GvHD, an increased infiltrate of T cells, mainly Th17 and CD8+ T cells, was observed in the ileocolonic mucosa of patients, while the number of immunomodulatory cells such as regulatory T-cells and type 3 innate lymphoid cells decreased. After FMT, a change in immune cell patterns was induced, depending on the clinical response. Conclusion: This study increases the knowledge about the crucial effects of antibiotics in patients given FMT for treatment refractory GI-GvHD and defines the characteristic alterations of ileocolonic mucosal immune cells in this setting.

[1]  G. Hill,et al.  Current Concepts and Advances in Graft-Versus-Host Disease Immunology. , 2021, Annual review of immunology.

[2]  A. Tomaszewska,et al.  Fecal microbiota transplantation in patients with acute and chronic graft‐versus‐host disease—spectrum of responses and safety profile. Results from a prospective, multicenter study , 2020, American journal of hematology.

[3]  C. Bock,et al.  Long-term skin-resident memory T cells proliferate in situ and are involved in human graft-versus-host disease , 2020, Science Translational Medicine.

[4]  B. Blom,et al.  Donor fecal microbiota transplantation ameliorates intestinal graft-versus-host disease in allogeneic hematopoietic cell transplant recipients , 2020, Science Translational Medicine.

[5]  W. Wiktor-Jedrzejczak,et al.  Eosinophilic gastroenteritis and graft‐versus‐host disease induced by transmission of Norovirus with fecal microbiota transplant , 2020, Transplant infectious disease : an official journal of the Transplantation Society.

[6]  R. Jenq,et al.  Microbiome-intestinal crosstalk during acute graft-versus-host disease (GVHD). , 2020, Blood.

[7]  M. Mihm,et al.  Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host-disease. , 2020, The Journal of clinical investigation.

[8]  M. Biernat,et al.  Fecal microbiota transplantation in the treatment of intestinal steroid-resistant graft-versus-host disease: two case reports and a review of the literature , 2020, The Journal of international medical research.

[9]  E. Diamandis,et al.  Drug-Resistant Bacteremia after Fecal Microbiota Transplant. , 2020, The New England journal of medicine.

[10]  M. Mohty,et al.  Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. , 2020, The New England journal of medicine.

[11]  Xiao-jun Huang,et al.  Treatment and unmet needs in steroid-refractory acute graft-versus-host disease , 2020, Leukemia.

[12]  Paul J. Martin,et al.  How I treat steroid-refractory acute graft-versus-host disease. , 2020, Blood.

[13]  Daigo Hashimoto,et al.  Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. , 2020, The New England journal of medicine.

[14]  P. Reddy,et al.  Short chain fatty acids: Postbiotics/metabolites and graft versus host disease colitis. , 2020, Seminars in hematology.

[15]  Miriam H. Huntley,et al.  Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant. , 2019, The New England journal of medicine.

[16]  H. Tilg,et al.  International consensus conference on stool banking for faecal microbiota transplantation in clinical practice , 2019, Gut.

[17]  L. French,et al.  Subcutaneous white adipose tissue of healthy young individuals harbors a leukocyte compartment distinct from skin and blood. , 2019, The Journal of investigative dermatology.

[18]  L. Kanz,et al.  Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation , 2019, Bone Marrow Transplantation.

[19]  M. Rescigno,et al.  Therapeutic faecal microbiota transplantation controls intestinal inflammation through IL10 secretion by immune cells , 2018, Nature Communications.

[20]  J. Ferrara,et al.  GVHD: biology matters. , 2018, Blood advances.

[21]  M. Hattori,et al.  Fecal microbiota transplantation with frozen capsules for a patient with refractory acute gut graft-versus-host disease. , 2018, Blood advances.

[22]  Depei Wu,et al.  Treating Steroid Refractory Intestinal Acute Graft-vs.-Host Disease With Fecal Microbiota Transplantation: A Pilot Study , 2018, Front. Immunol..

[23]  Asad Jehangir,et al.  A Systematic Review of the Efficacy and Safety of Fecal Microbiota Transplant for Clostridium difficile Infection in Immunocompromised Patients , 2018, Canadian journal of gastroenterology & hepatology.

[24]  Liangzhi Wen,et al.  Fecal Microbiota Transplantation Ameliorates Experimentally Induced Colitis in Mice by Upregulating AhR , 2018, Front. Microbiol..

[25]  André Karch,et al.  Colonic Butyrate-Producing Communities in Humans: an Overview Using Omics Data , 2017, mSystems.

[26]  A. Plantinga,et al.  Stool Microbiota at Neutrophil Recovery Is Predictive for Severe Acute Graft vs Host Disease After Hematopoietic Cell Transplantation , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  P. Neumeister,et al.  Repeated fecal microbiota transplantations attenuate diarrhea and lead to sustained changes in the fecal microbiota in acute, refractory gastrointestinal graft-versus-host-disease , 2017, Haematologica.

[28]  H. Tilg,et al.  European consensus conference on faecal microbiota transplantation in clinical practice , 2017, Gut.

[29]  M. Hattori,et al.  Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut. , 2016, Blood.

[30]  Y. Taur,et al.  Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice , 2016, Science Translational Medicine.

[31]  P. Oefner,et al.  Rifaximin preserves intestinal microbiota balance in patients undergoing allogeneic stem cell transplantation , 2016, Bone Marrow Transplantation.

[32]  J. Ritz,et al.  Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. , 2016, Blood.

[33]  Corinne Rossi,et al.  Gut microbiome derived metabolites modulate intestinal epithelial cell damage and mitigate Graft-versus-Host Disease , 2016, Nature Immunology.

[34]  L. Boon,et al.  Type 3 innate lymphoid cells maintain intestinal epithelial stem cells after tissue damage , 2015, The Journal of experimental medicine.

[35]  J. Mjösberg,et al.  Innate Lymphoid Cells in Graft‐Versus‐Host Disease , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[36]  Tariq Ahmad,et al.  Fatal Aspiration Pneumonia as a Complication of Fecal Microbiota Transplant. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  M. Robin,et al.  A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[38]  B. Blom,et al.  Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease. , 2014, Blood.

[39]  Daniel Wolff,et al.  Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[40]  M. Hattori,et al.  Characterization of the 17 strains of regulatory T cell-inducing human-derived Clostridia , 2014, Gut microbes.

[41]  Shashank Garg,et al.  Microbiota Dynamics in Patients Treated with Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection , 2013, PloS one.

[42]  M. Hattori,et al.  Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota , 2013, Nature.

[43]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[44]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.